Who
Elizabeth A. Garofalo
Director
Company insider
Files Form 4 as: Director, Alector; Director, Xenon Pharmaceuticals; Director, ACADIA Pharmaceuticals; Director, Exicure.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $227K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 29 Sep 2020
- Last trade
- 17 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 17 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —28,700 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —9,450 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —9,450 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —28,700 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Elizabeth A. Garofalo; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.